Oppenheimer Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Ionis Pharmaceuticals (NASDAQ:IONS) and raises the price target from $72 to $75.
April 09, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson reaffirmed an Outperform rating on Ionis Pharmaceuticals and increased the price target from $72 to $75.
The increase in the price target by a reputable analyst suggests a positive outlook on the stock's future performance. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100